AzTrials
AzTrials

PrematurityPhase 4lactoprenewNCT01172236

Supplementation With Lactoferrin in Preterm Newborns

A Phase 4 study testing Lactoferrin in people with Prematurity and Low Birth Weight, run by University of Siena.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done through the assessment of neuro-developmental follow-up. Read more about this study

Who is it for?
Ages 23 to 32 weeks
Conditions the study is for
Prematurity, Low Birth Weight
What is being tested?
Lactoferrin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,300 participants
Where
No sites listed yet
Study dates
Jan 2011to Jan 2013
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 23 to 32 weeks
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Newborns with a birthweight ≤ 1500 grand/or gestational age ≤ 32 weeks
  • Sign of the informed consent by parents

Who cannot join

  • Fetal-onset disorders and/or recognizable at birth
  • Milk intolerance
  • Family history of allergies
  • Use of infant formula supplemented with lactoferrin

About this study

The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done through the assessment of neuro-developmental follow-up.

The secondary objective is to identify a panel of markers for assessing oxidative stress and for a correlation with the lactoferrin antioxidant effect.

Read the detailed description

The study arises from the need to structure care to identify a product natural with antioxidant propriety that may reduce the extent of damage in perinatal neurological disorders related to oxidative stress by limiting the pain for infants and families and simultaneously reducing the cost to the SSN arising from standard pharmacological therapy and rehabilitation in the short and medium term. The research results will remain available to the scientific community and will not be used for profit or commercial. The iron (Fe) is the most abundant transition metal1 in the body and an essential element for growth and welfare of almost all life2 where he played a key role in many biochemical processes3. It is essential as cofactor in many enzymatic reactions and as catalyst in the processes of electron transport, yet is potentially toxic and rarely available. In the presence of oxygen Fe causes harmful action on the cell since it enhances the production by non-enzymatic reactive oxygen species. The hydroxyl radical in particular, can damage various cellular components such as DNA, proteins and membrane lipids. All bodies have therefore developed strategies that allow them to retain Fe was acquired in a soluble, nontoxic and in a form readily available. The Fe excess, also caused by weak bonds that the metal has with nonspecific and specific plasma proteins may carry out its negative effects by generating free radicals through the reactions of Fenton and Heber-Weiss4. Physiological requirements of Fe is higher during periods of rapid growth and differentiation, such as perinatal and nervous system that develops rapidly in late fetal life and early neonatal period, appears to be particularly sensitive to modulations of Fe contents5 In the newborn the inability to regulate, as necessary, the uptake of Fe by the immature gut may be the reason for failure and / or excess metal. Both situations may have adverse effects on neurological development of infants and in case of failure becomes irreversible even6-8 because any supplementation does not improve autcome9-11. In both cases the events that occur in early childhood have adverse effects on neuronal function in adults. The mechanism by which iron deficiency affects brain development is completely unknown but we know that can range up to a general lack metabolic errors of myelination and synaptogenesis and changes in specific funcions12 . It was also suggested that the adverse clinical outcomes in premature infants receiving blood transfusions and / or colonization13 may be related to oxidative damage14-17 <br>The main source of food for newborns is breast milk or formula. Breast milk contains heme Fe consequently the non-heme Fe, which is bound to milk proteins and other substances with lower molecular weight, is the main source of Fe in the diet of infants. The child is able to regulate the absorption of iron from the gut, in response to supplementation, only near the first year of life,18 so the inability of infants to regulate the intestinal absorption predisposes them to a deficiency when the Fe in the diet is insufficient, or an overload, when levels in the diet are high. It was also suggested that the enrichment of Fe in young children may lead to an increase in its plasma concentration and the formation of nonspecific compounds (nonspecific binding to proteins with low affinity bonds) that give rise to the so-called free Fe (NPBI) which originate from reactive oxygen species. Some authors have demonstrated increased oxidative stress in infants of very low birth weight who were subjected to a large oral iron supplementation, especially if breastfed seno.19-21 Although gestational age and some clinical treatments such as transfusions and ventilation considered because of an increased risk of oxidative damage Fe-indotto.22 Since the status of Fe in breast-fed term infants is usually satisfactory, at least until the sixth month, and an important part of Fe in human milk is bound to lactoferrin, has been previously suggested that the effect protective of human milk is related to the presence of this protein fixing most of the Fe and regulates its absorption. The lactoferrin is an iron-binding protein, naturally found in high concentrations in breast milk and in low concentrations in other fluids esocrini23. For the size and structure of lactoferrin is closely linked to another group of Fe-related protein, the transferrin and is considered by many as a member of this family. Lactoferrin binds iron with high affinity binding and its structure is unusually resistant to proteolytic degradation. Besides regulating the absorption of iron during inflammatory processes and infettivi24 performs several physiological functions including antibacterial, antifungal, antivirale25, antiparassitary26, antitumoral27, immunomodulator28-29. This ability antibacterial and antiviral properties, may explain the low prevalence and shorter duration of infection in breast-fed infants. In human milk lactoferrin plays an antioxidant sequestering free ions of Fe30 and thus preventing lipid peroxidation and subsequent milk oxidation31. Some AA.32 have shown this property in vitro using salts and Fe ions in the presence of a biological agent such as reducing ascorbato33. A recent study has also demonstrated its antioxidant effect in blood34. Again lactoferrin is able to bind free Fe, from binding studies, avoiding be sure to trigger a series of chain reactions that produce free radicals and thus reduces the damage induced by oxidative stress. This explains why breastfed children have significantly higher total antioxidant capacity and significantly lower index of oxidative stress. A recent study on infants supplied with formula supplemented with lactoferrin showed that presence of this protein helps the absorption of Fe in the small gut. The same study suggests that its activity could stimulate the proliferation and differentiation of mucosal cells in the gut35, thus increasing the surface and in turn increase the absorption of nutrients. Studies in pregnancy women 36 suggests that lactoferrin may have an anti-inflammatory effect, while also improving the Fe status of women.

Being tested
Lactoferrin
Medical subject headings
Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LactoferrinDrug

    Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.

    Control group: newborns (group B) will receive only standard therapy and they will be used as controls.

  • LactoferrinDrug

    Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.

Study groups in NCT01172236
Study groupRoleWhat they receive
LactoferrinExperimentalNot described
Receives: Drug: Lactoferrin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done trough the assessment of neuro-developmental follow-up.

    Measured: 12 months

Secondary outcomes (1)
  1. The secondary objective is to identify a panel of markers for assessing oxidative stress and for a correlation with the lactoferrin antioxidant effect.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2010 (estimated)
  2. Study startJan 2011
  3. Primary completionJan 2012
  4. Study completionJan 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
1,300 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01172236
Sponsor's protocol ID
NEO-LF100-2010
Acronym
lactoprenew
Status last verified
Apr 2010
First submitted
28 Jul 2010
Last updated
26 Mar 2020
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Lactoferrin in people with Prematurity and Low Birth Weight, run by University of Siena.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done trough the assessment of neuro-developmental follow-up. (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2020; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in